Zofin - ZEO ScientifiX
Alternative Names: Organicell Flow; ZofinLatest Information Update: 05 Apr 2024
At a glance
- Originator Organicell
- Developer Centers for Disease Control and Prevention; Organicell; ZEO ScientifiX
- Class Anti-infectives; Antirheumatics; Antivirals; Cardiovascular therapies; Immunotherapies; MicroRNAs; Proteins
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Chronic obstructive pulmonary disease; COVID 2019 infections; Osteoarthritis; SARS-CoV-2 acute respiratory disease
- Research Autoimmune disorders
- Discontinued Cardiovascular disorders; Influenza virus infections
Most Recent Events
- 30 Oct 2023 Organicell Regenerative Medicine suspends a phase I/II trial in Chronic obstructive pulmonary disease in USA (IV) (NCT05643729)
- 18 Oct 2023 Organicell completes a phase I/II trial in COVID-2019 infections in USA (IV) (NCT05228899)
- 01 Jul 2023 Organicell completes a phase I/II trial in COVID-2019 infections in USA (IV) (NCT04384445)